While Insas Berhad's (KLSE:INSAS) share price has underperformed the broader market over three years, its total shareholder return tells a different story. A closer look reveals a disconnect between stock performance and underlying business fundamentals, prompting investor scrutiny.
A revised price target for Haivision Systems (TSX:HAI) is shifting the investment narrative, prompting a closer look at the video streaming technology firm's prospects amid evolving market conditions.
A revised price target for industrial conglomerate Illinois Tool Works has refocused investor attention, prompting a fresh assessment of the company's strategic positioning and market sentiment.
Drivers across the Midwest are feeling the pinch as regional gasoline prices rose for a second consecutive week, with the current average now sitting 9 cents higher than last month. While still below the national average, the steady increase signals potential pressure on household budgets.
Bank of America has revised its price target for consumer goods giant Kimberly-Clark downward, citing sector-wide valuation pressures, even as the company reports resilient earnings and advances its transformation into a broader health and wellness player.
T-Mobile US faces a pivotal moment as aggressive industry pricing and a tempered 2026 financial forecast clash with its robust operational performance and network leadership, prompting a major investor exit and forcing a reevaluation of its growth narrative.
Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.
A critical measure of Bitcoin mining profitability has collapsed to its lowest level since late 2024, as miners grapple with falling BTC prices and severe operational disruptions from a major U.S. winter storm, according to analytics firm CryptoQuant.
Wells Fargo updates its long-term valuation for American Electric Power (AEP), raising its price target to $140, as the utility secures a major fuel cell investment and a 20-year power purchase agreement for a new Wyoming facility.
Truist Securities adjusted its price target for American Healthcare REIT (NYSE: AHR) downward slightly, while affirming a Buy rating. The move comes as the firm reassesses its outlook for the broader REIT sector heading into 2026.
The Producer Price Index jumped 0.5% last month, more than double November's increase, as rising costs for machinery, metals, and travel services pointed to persistent pipeline pressures for consumers.
Following a strategic adjustment to its share capital structure, China's leading online recruitment platform Kanzhun Limited sees sustained bullish sentiment from Wall Street, with a majority of analysts maintaining Buy ratings and forecasting significant upside.
While stocks priced between $10 and $50 can offer an appealing mix of accessibility and relative maturity, savvy investors know the sticker price is just the beginning. We examine one company in this range that appears poised for growth and two where the fundamentals warrant a closer, more cautious look.
USA Rare Earth Inc. (NASDAQ: USAR) sees its price target significantly raised by Canaccord Genuity and Benchmark following a landmark $1.6 billion commitment from the U.S. CHIPS Program, accelerating its plans to build a domestic rare earth supply chain.
Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.
Following a robust Q4 earnings beat, IBM's strategic focus on hybrid cloud, AI, and quantum computing earns a price target upgrade from Bank of America, with analysts citing improved growth and free cash flow trajectory.
As gold prices soar past $5,400 an ounce before a sharp pullback, a global rush is underway. From Parisian boutiques to Main Street dealers, consumers are capitalizing on heirlooms or diving into the market, driven by geopolitical tensions and economic uncertainty.
